CD-2394 is a novel synthetic retinoid compound. This compound's treatment reduces the number of cells in the G2M-phase, suggesting a slowdown in cell proliferation. Additionally, normal differentiation is inhibited, while keratin 13 expression is observed in CD-2394-treated samples, a phenomenon not seen in other treated skin samples. This indicates CD-2394 may induce an embryonic differentiation pathway distinct from normal or regenerative differentiation.